Standalone Revenue Up, Par Profit Mein Gadbad!
Apni company Genpharmasec ne Q3 FY26 mein apne standalone revenue mein tagda jump dikhaya hai, jo pichle saal ke muqable 14.39% zyada hai, pohanch gaya ₹5,900.32 Lakhs tak. Total income bhi 13.34% badhi hai. Lekin, yahan ek badi chinta ki baat hai ki profitability mein giri aayi hai. Profit Before Tax (PBT) 71.56% gir kar sirf ₹48.77 Lakhs reh gaya hai, aur Profit After Tax (PAT) bhi 31.54% kam hokar ₹75.64 Lakhs ho gaya. Share ka EPS bhi ₹0.01 ho gaya hai.
Consolidated Picture Thodi Chintajanak
Jab consolidated figures dekhe jaate hain, toh kahani thodi alag hai. Consolidated revenue 17.73% se gir kar ₹3,982.81 Lakhs pe aa gaya hai. Aur sabse badi baat, company ne ₹133.23 Lakhs ka PBT loss report kiya hai, jabki pichle saal isi period mein ₹126.50 Lakhs ka profit tha. Bottom line par, company ₹75.71 Lakhs ka net loss report kar rahi hai, jo pichle saal ke ₹173.05 Lakhs ke profit se bilkul alag hai. EPS bhi ₹(0.02) ho gaya hai.
Accounting Policy Change Aur Nayi Subsidiary Ki Khabrein
Iske alawa, company ne kuch accounting policies mein bhi change kiya hai. Kuch equity shares ko 'Inventories' se 'Financial Investments' mein reclassify kiya gaya hai, jisse inventories mein ₹89.32 Lakhs ki kami aayi hai. Aur haan, July 25, 2025 ko Derren Healthcare Private Limited mein 70% stake acquire karne ke baad woh company ki subsidiary ban gayi hai.
Management ne yeh bhi assess kiya hai ki naye Labour Codes ka gratuity obligations par koi bada impact nahi padega. Filhal, management ne future performance ke liye koi guidance nahi di hai, toh investors ko current performance ko dhyan se dekhna padega.